This New GLP-1 Drug Just Made Novo Nordisk Furious | $HIMS $NOVO

Travis Hoium analyzes the recent developments surrounding Hims & Hers' new compounded oral GLP-1 product and the legal challenges it faces from Novo Nordisk and the FDA. He explains that Hims & Hers is using liposomal technology from Strive to circumvent Novo Nordisk's SNAC technology patent. Hoium suggests that while the FDA's concerns about unapproved drugs are valid, off-label prescriptions are common, and Hims & Hers is operating within the legal boundaries of compounding laws. He also points out that changing these laws would require congressional action, which is difficult. Despite the risks, Hoium views Hims & Hers' actions as a disruptive move to increase access and lower prices for consumers, similar to companies like Tesla and Uber challenging existing regulations.